✦ LIBER ✦

Where are we in the search for noninvasive nonalcoholic steatohepatitis biomarkers?

✍ Scribed by José M. Mato; Shelly C. Lu

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 72 KB
Volume: 54
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.24642

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Combination therapy for erectile dysfunc

Combination therapy for erectile dysfunction: Where we are and what’s in the future

✍ Ajay Nehra; Haluk Kulaksizoglu 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 275 KB

Where are we now and where do we go next

Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence?

✍ R. L. Williams; W. Adams; M-L. Chen; D. Hare; A. Hussain; L. Lesko; R. Patnaik; 📂 Article 📅 2000 🏛 Springer-Verlag 🌐 English ⚖ 706 KB

Discussion: Newer bisphosphonates in the

Discussion: Newer bisphosphonates in the treatment of paget's disease of bone: Where we are and where we want to go

✍ Andreas Grauer; Henry Bone; Eugene V. Mccloskey; Michael Mcclung; Donald H. Gutt 📂 Article 📅 1999 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 569 KB

Atorvastatin decreases serum levels of a

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH

✍ Yuki Kimura; Hideyuki Hyogo; Sho-ichi Yamagishi; Masayoshi Takeuchi; Tomokazu Is 📂 Article 📅 2010 🏛 Springer Japan 🌐 English ⚖ 202 KB

Application of proteomics for the identi

Application of proteomics for the identification of biomarkers in amniotic fluid: are we ready to provide a reliable prediction?

✍ George Th. Tsangaris; Athanasios K. Anagnostopoulos; Georgia Tounta; Aris Antsak 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 210 KB